ASH 2012 home

Article

Cancer Network presents exclusive coverage from the American Society of Hematology (ASH) annual meeting. We'll bring you onsite reports as we cover the latest research, trials, scientific advances, and controversies that are changing the way hematologic malignancies are managed and treated.Check back here daily during the meeting and watch your inbox for our exciting reports from the ASH 2012 meeting.

Cancer Network presents exclusive coverage from the American Society of Hematology (ASH) annual meeting. We'll bring you onsite reports as we cover the latest research, trials, scientific advances, and controversies that are changing the way hematologic malignancies are managed and treated.

Check back here daily during the meeting and watch your inbox for our exciting reports from the ASH 2012 meeting.

Recent Videos
212Pb-DOTAMTATE showed “unexpectedly good” outcomes among those with gastroenteropancreatic neuroendocrine tumors, said Mary Maluccio, MD, MPH, FACS.
4 experts are featured in this series.
4 experts are featured in this series.
2 experts are featured in this series.
4 experts in this video
7 experts are featured in this series.
2 KOLs are featured in this series.
Trials at scale can be conducted in middle-income, low-middle-income, and even lower-income countries if you organize a trial ecosystem.
2 experts are featured in this series.
Related Content
Phase 3 data demonstrate PD-L1 positivity and BRCA mutation status as prognostic for improved overall survival regardless of treatment arm.

Atezolizumab Combo Elicits No Significant Benefit in Ovarian Cancer

Russ Conroy
November 3rd 2025
Article

Phase 3 data demonstrate PD-L1 positivity and BRCA mutation status as prognostic for improved overall survival regardless of treatment arm.

Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.

How Will Gastrointestinal Cancer Standards of Care Change? An ESMO Recap

Nicholas James Hornstein, MD, PhD;Timothy Brown, MD;Udhayvir S. Grewal, MD
November 3rd 2025
Podcast

Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.

A shorter course of radiotherapy may provide similar oncological outcomes as long-course treatment for older patients with locally advanced rectal cancer.

Short-Course Radiation May Be Feasible in Older Rectal Cancer Population

Russ Conroy
November 3rd 2025
Article

A shorter course of radiotherapy may provide similar oncological outcomes as long-course treatment for older patients with locally advanced rectal cancer.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

Data from a phase 2 study support further development of sacituzumab tirumotecan plus pembrolizumab in metastatic castration-resistant prostate cancer.

Sac-TMT Combo Produces Encouraging Activity in Pretreated Metastatic CRPC

Russ Conroy
November 2nd 2025
Article

Data from a phase 2 study support further development of sacituzumab tirumotecan plus pembrolizumab in metastatic castration-resistant prostate cancer.

Molecular Insights Into Cancer Cachexia: An Evolution in Identifying the Syndrome

Molecular Insights Into Cancer Cachexia: An Evolution in Identifying the Syndrome

Ariana Pelosci
November 2nd 2025
Article

Vickie Baracos, PhD, discusses recent results that investigate cancer cachexia and how the RNome of the muscle plays a role.